Delcath Systems, Inc. (DCTH)
After hours:
| Previous close | 5.40 |
| Open | 5.50 |
| Bid | 5.41 x 100 |
| Ask | 5.48 x 100 |
| Day's range | 5.31 - 5.57 |
| 52-week range | 2.25 - 7.99 |
| Volume | |
| Avg. volume | 207,993 |
| Market cap | 151.147M |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.94 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.40 |
PR NewswireDelcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award, previously approved by the Company's Compensation Committee, as a material inducement to the employment of one individual whose employment commenced in March 2024.
- GuruFocus.com
Delcath Systems Inc (DCTH) Reports Mixed Year-End Financials Amidst Strategic Advancements
Revenue Falls Short While R&D Expenses Decrease Compared to Analyst Estimates
- PR Newswire
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
